



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
29.03.2023 Bulletin 2023/13

(45) Date of publication and mention
of the grant of the patent:
15.03.2023 Bulletin 2023/11

(21) Application number: **16721609.2**

(22) Date of filing: **29.04.2016**

(51) International Patent Classification (IPC):
A61K 38/10 ^(2006.01) **A61K 38/12** ^(2006.01)
C07K 7/54 ^(2006.01) **C07K 7/64** ^(2006.01)

(52) Cooperative Patent Classification (CPC):
C07K 7/08; A61K 9/0031; A61K 38/10;
A61K 38/12; A61P 1/10; A61P 35/00; A61K 38/00

(86) International application number:
PCT/US2016/030061

(87) International publication number:
WO 2016/178979 (10.11.2016 Gazette 2016/45)

(54) **COMPOSITIONS FOR COLON CLEANSING AND THE TREATMENT OF GASTROINTESTINAL DISORDERS**

ZUSAMMENSETZUNGEN ZUR DICKDARMREINIGUNG UND BEHANDLUNG VON
GASTROINTESTINALEN STÖRUNGEN

COMPOSITION POUR LE NETTOYAGE DU CÔLON ET LE TRAITEMENT DE TROUBLES
GASTRO-INTESTINAUX

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: **01.05.2015 US 201562156077 P**

(43) Date of publication of application:
07.03.2018 Bulletin 2018/10

(73) Proprietor: **Ironwood Pharmaceuticals, Inc.**
Boston, MA 02110 (US)

(72) Inventors:
• **CURRIE, Mark, G.**
Boston, MA 02129 (US)
• **SOLINGA, Robert**
Brookline, MA 02445 (US)
• **LEITHEISER, Christopher**
Arlington, MA 02474 (US)

(74) Representative: **Mathys & Squire**
The Shard
32 London Bridge Street
London SE1 9SG (GB)

(56) References cited:
WO-A1-2016/015055 WO-A2-2014/131024

- **MOHAMMED AKHTER HOSSAIN ET AL: "Solid phase synthesis and structural analysis of novel A-chain dicarba analogs of human relaxin-3 (INSL7) that exhibit full biological activity", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 7, no. 8, 1 April 2009 (2009-04-01), pages 1547-1553, XP055082660, ISSN: 1477-0520, DOI: 10.1039/b821882j**
- **GIOVANNI PITARI: "Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis", DRUG DESIGN, DEVELOPMENT AND THERAPY, 19 April 2013 (2013-04-19), pages 351-360, XP055148568, DOI: 10.2147/DDDT.S32252**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).